TOPAMAX SPRINKLE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TOPAMAX SPRINKLE (TOPAMAX SPRINKLE).
Topiramate is a sulfamate-substituted monosaccharide that blocks voltage-gated sodium channels, enhances GABA-A receptor activity, antagonizes AMPA/kainate glutamate receptors, and inhibits carbonic anhydrase (isoenzymes II and IV).
| Metabolism | Hepatic via CYP3A4 isoenzyme (minor), glomerular filtration and tubular reabsorption with 70% excreted unchanged in urine. |
| Excretion | Approximately 70% of a dose is excreted unchanged in the urine; the remainder is metabolized and eliminated via renal and biliary routes. Renal elimination of both parent drug and metabolites accounts for ~80%, with minimal fecal excretion. |
| Half-life | Terminal elimination half-life is approximately 21 hours in adults with normal renal function. This allows for twice-daily dosing. Half-life increases significantly in renal impairment (e.g., 36-46 hours in moderate to severe impairment). |
| Protein binding | Approximately 15-41% bound to plasma proteins, primarily albumin. Binding is concentration-independent over the therapeutic range. |
| Volume of Distribution | Volume of distribution is approximately 0.6-0.8 L/kg, indicating distribution into total body water. This suggests good tissue penetration, including into the central nervous system. |
| Bioavailability | Oral bioavailability is approximately 80% (range 70-90%) for Topamax Sprinkle capsules. Bioavailability is not affected by food, but administration with food may reduce peak concentration but not overall absorption. |
| Onset of Action | Oral: Clinical effects (e.g., seizure reduction, migraine prophylaxis) may be observed within 1-2 weeks of achieving therapeutic doses, but full effect may require several weeks of dose titration. |
| Duration of Action | Duration of action is approximately 12-24 hours with twice-daily dosing, consistent with half-life. Steady-state is reached in about 4-5 days in patients with normal renal function. |
| Molecular Weight | 339.4 |
Initial dose: 25-50 mg orally once daily at bedtime for 1 week; then increase by 25-50 mg/day at weekly intervals to recommended maintenance dose of 200-400 mg/day in 2 divided doses.
| Dosage form | CAPSULE |
| Renal impairment | CrCl <70 mL/min: reduce dose by 50%. CrCl <30 mL/min: use 50% of recommended starting dose and titrate slowly. |
| Liver impairment | Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: reduce dose by 75%. |
| Pediatric use | Ages 2-16 years: initial 1-3 mg/kg/day (max 25 mg/day) at bedtime; increase by 1-3 mg/kg/day at weekly intervals to maintenance of 5-9 mg/kg/day in 2 divided doses. Max dose 400 mg/day. |
| Geriatric use | Initiate at lower end of dosing range (25 mg/day). Titrate more slowly (every 2 weeks) due to increased sensitivity and reduced renal function. |
| 1st trimester | Risk of oral clefts (cleft lip/palate) if used in first trimester. Use only if benefit outweighs risk. |
| 2nd trimester | Use with caution; may be associated with decreased fetal growth and minor anomalies. |
| 3rd trimester | Use with caution; may cause neonatal hemorrhage due to vitamin K deficiency, and metabolic acidosis. |
Clinical note
Comprehensive clinical and safety monograph for TOPAMAX SPRINKLE (TOPAMAX SPRINKLE).
| Placental transfer | Topiramate crosses the placenta readily; fetal plasma concentrations similar to maternal levels. |
| Breastfeeding | Topiramate is excreted into breast milk. Infant serum levels can be low but monitor for adverse effects such as diarrhea, drowsiness, and irritability. Consider using lowest effective dose, and monitor infant growth and development. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to topiramate or any excipientsConcurrent use with metformin (potential for metabolic acidosis)
| Precautions | Acute myopia and secondary angle-closure glaucoma, Oligohidrosis and hyperthermia (especially in pediatric patients), Metabolic acidosis (increased risk with ketogenic diet), Suicidal behavior and ideation, Cognitive/neuropsychiatric adverse reactions (including speech/language disorders, psychomotor slowing, somnolence/fatigue), Fetal toxicity (cleft lip/palate) and decreased fetal weight, Kidney stones (due to carbonic anhydrase inhibition), Monitor serum bicarbonate levels, Dose adjustment required for renal impairment (CrCl <70 mL/min) |
| Food/Dietary | Topiramate absorption is not significantly affected by food. However, the sprinkle capsule contents should be mixed with a small amount of soft food (e.g., applesauce, yogurt) for ease of administration. Avoid alcohol as it may exacerbate central nervous system depression and metabolic acidosis. Maintain adequate hydration to prevent nephrolithiasis; acidic foods (e.g., cranberry juice) may theoretically reduce stone risk by acidifying urine, but evidence is insufficient. |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category D. First trimester exposure associated with increased risk of oral clefts (cleft lip/palate), approximately 1-2% absolute risk. Second and third trimester exposure may cause fetal growth restriction, hypospadias, and minor anomalies. Use only if benefit outweighs risk; consider alternative anticonvulsants. |
| Fetal Monitoring | Monitor maternal serum topiramate concentrations periodically (goal 2-5 mcg/mL). Obtain high-resolution fetal ultrasound at 18-20 weeks to screen for anomalies. Monitor fetal growth throughout pregnancy. After delivery, monitor neonate for withdrawal symptoms (irritability, hypertonia, tremors) and hypoglycemia. |
| Fertility Effects | Topiramate may induce oligomenorrhea or amenorrhea and reduce contraceptive efficacy of oral contraceptives containing ethinyl estradiol (dose-dependent). Advise women of childbearing potential to use adequate contraception. In men, no significant impact on fertility reported. |
| Clinical Pearls | Topiramate (TOPAMAX SPRINKLE) requires titration to minimize adverse effects. Monitor renal function and serum bicarbonate levels due to risk of metabolic acidosis. Avoid abrupt discontinuation to prevent seizure rebound. Sprinkle capsules can be opened and mixed with soft food for ease of administration. Contraindicated in patients with recent alcohol use or in those with metabolic acidosis. Use with caution in patients with kidney stones, as topiramate increases urinary pH and promotes calcium phosphate stone formation. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly to avoid withdrawal seizures. · Sprinkle capsule contents on a spoonful of soft food (e.g., applesauce, pudding) and swallow immediately without chewing. · Drink plenty of fluids to reduce risk of kidney stones. · Report any unexplained fever, fatigue, or changes in vision (acute myopia, angle-closure glaucoma). · Avoid alcohol as it may increase central nervous system depression and risk of metabolic acidosis. · Monitor for signs of metabolic acidosis: fast breathing, confusion, unusual tiredness. · Use effective contraception if of childbearing potential; topiramate may decrease oral contraceptive efficacy and cause fetal harm. · May cause dizziness, drowsiness, or blurred vision; avoid driving until effects are known. |